ARM011 not checked

TriArm Therapeutics (Taiwan) Limited

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“ARM011 is an autologous, CD19 targeted CAR T-cell product developed on fast-in-time (FIT) platform-a non-viral, 2-day rapid manufacturing process”In the company’s words, NCT07066397 on ClinicalTrials.gov
Tested for
Acute Lymphoblastic Leukemia
Main trialPhase 1
“This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.”In the company’s words, NCT07066397 on ClinicalTrials.gov

Other drugs for Acute Lymphoblastic Leukemia

All 58 drugs for Acute Lymphoblastic Leukemia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 1 Apr 2028 A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow ARM011

Following is part of Solo: you see every change to ARM011 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in